Proteon logo     Print Page | Close Window

SEC Filings

S-1
PROTEON THERAPEUTICS INC filed this Form S-1 on 09/16/2014
Entire Document
 

Table of Contents

 


THE OFFERING

Common stock we are offering

                          shares

Common stock outstanding after giving effect to this offering

 

                        shares

Option to purchase additional shares

 

The underwriters have a 30-day option to purchase a total of                additional shares of common stock.

Use of proceeds

 

We estimate that our net proceeds from this offering will be approximately $             million at an assumed initial public offering price of $            per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We expect to use the net proceeds of this offering to accelerate the commencement of our second Phase 3 clinical trial of PRT-201, to accelerate our chemistry and manufacturing controls activities, to fund additional research and development activities and for other general corporate purposes. See "Use of Proceeds."

Risk factors

 

See "Risk Factors" beginning on page 12 and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common stock.

Proposed NASDAQ Global Market Symbol

 

"PRTO"



        In this prospectus, unless otherwise indicated, the number of shares of common stock outstanding and the other information based thereon is based on                                    shares of common stock outstanding as of August 31, 2014 and does not reflect:

    17,982,120 shares of common stock issuable upon exercise of stock options outstanding as of August 31, 2014 at a weighted-average exercise price of $0.22 per share;
    10,471,282 shares of our common stock issuable upon exercise of warrants with a weighted-average exercise price of $0.29 per share that we expect to be exercised prior to the closing of this offering;
    18,361 shares of common stock reserved for issuance pursuant to future equity awards under our 2006 Equity Incentive Plan; and
    shares of common stock reserved for future issuance under our 2014 Equity Incentive Plan, which will become effective immediately prior to the closing of this offering (including            shares of common stock reserved for issuance under our 2006 Equity Incentive Plan, which will be added to the shares reserved under the 2014 Equity Incentive Plan upon its effectiveness).

        Unless otherwise indicated, all information in this prospectus reflects or assumes the following:

    the amendment and restatement of our certificate of incorporation and bylaws, which will occur immediately prior to the closing of this offering;
    the conversion of all of our outstanding shares of our preferred stock into 134,918,694 shares of common stock, including the conversion of our Series D convertible preferred stock on an assumed one-for-one basis which will occur automatically upon the closing of this offering. See

 

8